ERBB2 and carcinoma: As a pilot study, we sought to investigate the potential clinical utility of evaluating HER2-PID scores in the pretreatment biopsies from 34 HER2-positive carcinomas that had undergone neoadjuvant trastuzumab-based chemotherapy.